Skip to content

Viridian Therapeutics (VRDN) Stock Climbs After Pricing Public Offering

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company, has seen its shares rally premarket after announcing the pricing of its underwritten public offering.

Viridian is selling approximately 6.2 million shares at a public offering price of $11.00 per share and 23,126 shares of series B preferred stock for $733.37 per share, which are convertible into approximately 1.5 million shares of common stock.

The company has also granted the underwriters a 30-day option to purchase an additional 1.6 million shares of common stock at the public offering price. Jefferies, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering.

Viridian expects to raise around $85 million.

The firm intends to use the proceeds to advance its VRDN-001 and VRDN-002 programs and the preclinical development of its VRDN-004 and VRDN-005 programs as well as working capital and general corporate purposes.

Viridian shares are up 29.28% premarket at $13.82.

Should You Invest in Viridian Therapeutics Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.